Intellia Therapeutics, Inc.
General ticker "NTLA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.2B (TTM average)
Intellia Therapeutics, Inc. follows the US Stock Market performance with the rate: 36.4%.
Estimated limits based on current volatility of 3.5%: low 8.73$, high 9.61$
Factors to consider:
- Total employees count: 403 (-23.4%) as of 2024
- Top business risk factors: Economic downturns and volatility, Regulatory and compliance, Market acceptance, Liquidity and credit risks, Cybersecurity threats
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [7.02$, 19.68$]
- 2025-12-31 to 2026-12-31 estimated range: [5.69$, 15.89$]
Financial Metrics affecting the NTLA estimates:
- Negative: with PPE of -2.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -29.52 <= 0.33
- Positive: Investing cash flow per share per price, % of 10.63 > -0.66
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 73.21 > 63.39
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term NTLA quotes
Long-term NTLA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $52.12MM | $36.27MM | $57.88MM |
| Operating Expenses | $510.29MM | $551.57MM | $592.14MM |
| Operating Income | $-458.16MM | $-515.29MM | $-534.26MM |
| Non-Operating Income | $-16.02MM | $34.10MM | $15.24MM |
| R&D Expense | $419.98MM | $435.07MM | $466.31MM |
| Income(Loss) | $-474.19MM | $-481.19MM | $-519.02MM |
| Profit(Loss)* | $-474.19MM | $-481.19MM | $-519.02MM |
| Stockholders Equity | $1,235.58MM | $1,050.17MM | $871.96MM |
| Assets | $1,520.11MM | $1,300.98MM | $1,191.02MM |
| Operating Cash Flow | $-333.29MM | $-394.09MM | $-348.88MM |
| Capital expenditure | $58.39MM | $13.98MM | $5.78MM |
| Investing Cash Flow | $160.31MM | $-31.35MM | $125.57MM |
| Financing Cash Flow | $582.96MM | $130.32MM | $185.75MM |
| Earnings Per Share** | $-6.16 | $-5.42 | $-5.25 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.